U.S. biopharmaceutical company Gilead has entered into a definitive agreement to acquire Tubulis GmbH. Tubulis was spun off in 2019 from the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) and LMU Munich and develops next-generation…
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly into human cells and can repair the chloride channel…
APPLICATION/NOMINATION PERIOD: 02 FEBRUARY - 30 APRIL 2026 (EXTENDED❗️)
Researchers from the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) and other partner institutions of the German Center for Diabetes Research (DZD) have now identified a previously unknown function of the PICALM protein in skeletal…
“Lusatia has the potential to be a pioneer by national standards. The principles are transferable: Networking, administrative relief and patient-centered care work everywhere.”
Helmholtz researchers have created the first detailed protein map of specific sensory neurons that trigger pain. Their study, published in “Nature Communications,” will help researchers better understand the molecular mechanisms of chronic…
Leading European microphysiological systems (MPS) companies have announced the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world’s first industry association representing MPS providers. Founding members include…
One of the key challenges in brain cancer research is the limited availability of preclinical models. Dynamic42 GmbH, based in Jena, Germany, and EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH are addressing this gap through a new…
The Einstein Center Digital Future, known as the ECDF, is a Berlin-based centre for digitalisation research. It stands for independent, interdisciplinary research into the shaping and critical reflection of digital transformation, developed in…
Presentation on CRT-NEXT Study at ACC Conference Highlights Similar Primary Outcomes Compared to Conventional CRT-D, Fewer Atrial‑Lead Complications and Shorter Procedures with 2-Lead CRT-D System
